发明授权
US07635689B2 Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
有权
用于治疗黄病毒科感染的改良的2'和3'-核苷前体药物
- 专利标题: Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
- 专利标题(中): 用于治疗黄病毒科感染的改良的2'和3'-核苷前体药物
-
申请号: US11005445申请日: 2004-12-06
-
公开(公告)号: US07635689B2公开(公告)日: 2009-12-22
- 发明人: Paola LaColla , Richard Storer , Gilles Gosselin , Jean-Pierre Sommadossi
- 申请人: Paola LaColla , Richard Storer , Gilles Gosselin , Jean-Pierre Sommadossi
- 申请人地址: US MA Cambridge IT Cagliari FR Paris FR Montpellier
- 专利权人: Idenix Pharmaceuticals, Inc.,Universita Degli Studi di Cagliari,Centre National de la Recherche Scientifique,L'Universite Montpellier II
- 当前专利权人: Idenix Pharmaceuticals, Inc.,Universita Degli Studi di Cagliari,Centre National de la Recherche Scientifique,L'Universite Montpellier II
- 当前专利权人地址: US MA Cambridge IT Cagliari FR Paris FR Montpellier
- 代理机构: Jones Day
- 主分类号: A01N43/04
- IPC分类号: A01N43/04 ; A61K31/70
摘要:
2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.